Sacituzumab Tirumotecan vs MMAE-ADCs in Advanced Urothelial Carcinoma (FUSCC-SPARE-UC-01)

NCT07662863 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

75

Enrollment

OTHER

Sponsor class

Conditions

Bladder Cancer
Metastatic Urothelial Carcinoma
Urothelial Carcinoma
Peripheral Neuropathy

Interventions

DRUG: Sacituzumab Tirumotecan
DRUG: MMAE-based ADC
DRUG: Sacituzumab Tirumotecan (Observational Cohort)

Sponsor

Fudan University